Evaluation of TXA Prior to Surgery in the Geriatric Hip Fracture Population

Completed · Phase 3 · Has a placebo group

Conditions studied: Hip Fractures

In brief

The overall design of the study is a prospective, double-blinded, randomized study in the geriatric hip fracture population comparing those who receive intravenous tranexamic acid prior to incision to those who receive a placebo.

Key facts

Study ID

NCT03923959

Run by

Lancaster General Hospital

People needed

283

Starts

2020-02-01

Expected to finish

2022-12-09

Last updated by the study team

2024-10-10

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Provision of written informed consent
• Age > or = to 65 years
• Hip fracture location within the femoral neck, intertrochanteric, and subtrochanteric regions
• Indication for one of the following surgical interventions: hemiarthroplasty, total hip replacement, sliding plate and screw fixation, or intramedullary fixation

You may not qualify if…

• Indication for closed reduction or percutaneous screw
• Allergy to TXA
• Cerebrovascular accident/stroke, active coronary disease/myocardial infarction, or deep vein thrombosis/pulmonary emboli within one (1) month of the fracture
• Presence of hypercoaguable disorder, including cancer (active disease), elevated blood homocysteine levels, antiphospholipid antibody syndrome and inherited protein deficiencies (antithrombin III, factor V Leiden, protein S \& C deficiencies, prothrombin gene mutation)

Where it is running

• Lancaster General Heatlh / Penn Medicine — Lancaster, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.